Table 4—

Impact of clinical lipodystrophy on metabolic parameters in those with and without metabolic syndrome in the Lipodystrophy Case Definition Cohort by IDF criteria

Metabolic syndrome
No metabolic syndrome
LipodystrophyNo lipodystrophyP valueLipodystrophyNo lipodystrophyP value
n8331368396
Total cholesterol (mmol/l)5.7 ± 0.25.5 ± 0.30.675.5 ± 2.05.1 ± 1.00.002
LDL cholesterol (mmol/l)3.0 ± 1.03.0 ± 1.00.483.1 ± 1.03.0 ± 1.00.35
HDL cholesterol (mmol/l)0.96 ± 0.31.02 ± 0.280.331.1 ± 0.31.3 ± 0.4<0.0001
Triglycerides (mmol/l)3.6 ± 2.02.9 ± 2.00.093.2 ± 4.01.9 ± 2.0<0.0001
Glucose (mmol/l)5.8 ± 2.05.7 ± 2.00.755.2 ± 1.04.8 ± 0.7<0.0001
Insulin (mIU/l)160 ± 179119 ± 670.22103 ± 16769 ± 950.002
C-peptide (ng/ml)2.7 ± 72.0 ± 20.591.4 ± 2.01.0 ± 1.00.003
Insulin resistance (HOMA)6.7 ± 94.2 ± 20.143.7 ± 7.42.2 ± 3.00.001
Leptin (ng/ml)8.8 ± 106.8 ± 50.343.6 ± 5.04.7 ± 7.00.04
Adiponectin (μg/ml)11 ± 715 ± 100.0112 ± 1018 ± 10<0.0001
  • Data are means ± SD. HOMA, homeostasis model assessment.